Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/1/2018
SIETES contiene 92186 citas

 
 
 1 a 20 de 26 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]
2. Cita con resumen
Anónimo. Bévacizumab et cancer épithélial de l'ovaire résistant aux sels de platine. Prescrire 2015;35:656-7. [Ref.ID 99713]
5.
Anónimo. Topotécane. Cancers du col métastasés ou en rechute: pas de progrès. Prescrire 2008;28:336. [Ref.ID 82816]
6.
Mayor S. More cancer patients in England are getting approved drugs. BMJ 2006;333:671. [Ref.ID 78231]
8. Cita con resumen
Pizzolato J F, Saltz LB. The camptothecins. Lancet 2003;361:2235-42. [Ref.ID 66202]
9.
Ulukan H, Swaan PW. Camptothecins: a review of their chemotherapeutic potential. Drugs 2002;62:2039-57. [Ref.ID 63502]
10. Cita con resumen
Zackrisson A-L, Malmström H, Peterson C. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. Eur J Clin Pharmacol 2002;58:103-8. [Ref.ID 61917]
11.Tiene citas relacionadas Cita con resumen
Martin DK, Pater J L, Singer PA. Priority-setting decisions for new cancer drugs: a qualitative case study. Lancet 2001;358:1676-81. [Ref.ID 59944]
12.Tiene citas relacionadas Cita con resumen
Crown J. A "bureausceptic" view of cancer drug rationing. Lancet 2001;358:1660. [Ref.ID 59939]
13.
van den Bongard HJGD, Mathôt RAA, Beijnen JH, Schellens JHM. Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet 2000;39:345-67. [Ref.ID 55958]
14. Cita con resumen
Anónimo. Hycamtin for non-small-cell lung cancer. Scrip 2000;2584:26. [Ref.ID 53573]
15.
Anónimo. Cancer programme for UK NICE. Scrip 2000;2558:2. [Ref.ID 51850]
17.
Ormrod D, Spencer CM. Topotecan: a review of its efficacy in small cell lung cancer. Drugs 1999;58:533-51. [Ref.ID 46234]
18.
Cersosimo RJ. Topotecan: a new topoisomerase I inhibiting antineoplastic agent. Ann Pharmacother 1998;32:1334-43. [Ref.ID 42216]
19.
Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 1998;56:1019-38. [Ref.ID 42053]
20.
Brogden RN, Wiseman LR. Topotecan: a review of its potential in advanced ovarian cancer. Drugs 1998;56:709-23. [Ref.ID 40864]
Seleccionar todas
 
 1 a 20 de 26 siguiente >>